Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.50 |
| ▸ | TET3 | O43151 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL123090 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL3408017 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL637799 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL3408016 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL28831630 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL13570956 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL7574683 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL17135308 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL10884230 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3SLC22A6TET1 | |
| Malic Acid SCHEMBL9478602 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3SLC22A6TET1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110366597-B | Blood profiling with protease inhibitors | 善威生物私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240060997-A1 | Blood Preparation and Profiling | SANGUI BIO PTY LTD (AU) | 2024-02-22 | — | — | US | disclosed |
| US-11693006-B2 | Blood profiling with protease inhibitors | SANGUI BIO PTY. LTD (AU) | 2023-07-04 | — | — | US | disclosed |
| EP-4009047-A1 | BLOOD PREPARATION AND PROFILING | Sangui Bio Pty. Ltd (AU) | 2022-06-08 | — | — | EP | disclosed |
| US-11243218-B2 | Blood preparation and profiling | Sangui Bio Pty Ltd. (AU) | 2022-02-08 | — | — | US | disclosed |
| CN-114019171-A | Blood preparation and profiling | 善威生物私人有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-108434126-B | Dry powder formulations and methods for treating pulmonary diseases | 普马特里克斯营业公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3359962-B1 | BLOOD PREPARATION AND PROFILING | SANGUI BIO PTY LTD (AU) | 2021-11-17 | — | — | EP | disclosed |
| EP-3470057-B1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | PULMATRIX OPERATING CO INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20130243828-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013130767-A1 | INHALABLE DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130213398-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX OPERATING COMPANY, INC. | 2013-08-22 | — | — | US | disclosed |
| EP-2621488-A1 | CATIONIC DRY POWDERS | Pulmatrix, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2611438-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012050945-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120064126-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2012030664-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2410981-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111680-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243828-A1 | CATIONIC DRY POWDERS | CA2, ORAI1, TRPV5 | SMN1; SMN2 2385/4885TET2 4115/4885TET3 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.